AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.6 |
Market Cap | 25.46M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -0.64 |
PE Ratio (ttm) | -1.28 |
Forward PE | n/a |
Analyst | Hold |
Ask | 0.88 |
Volume | 169,827 |
Avg. Volume (20D) | 107,091 |
Open | 0.82 |
Previous Close | 0.82 |
Day's Range | 0.79 - 0.85 |
52-Week Range | 0.62 - 1.88 |
Beta | undefined |
About DRRX
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in...
Analyst Forecast
According to 2 analyst ratings, the average rating for DRRX stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 509.61% from the latest price.
Next Earnings Release
Analysts project revenue of $6.91M, reflecting a 158.90% YoY growth and earnings per share of -0.02, making a -80.00% decrease YoY.